salivary gland cancer (Cancer)
Information
- Disease name
- salivary gland cancer
- Disease ID
- DOID:8850
- Description
- "An oral cavity cancer that is located_in the salivary gland." [url:http\://www.cancer.gov/dictionary?CdrID=446528]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02069730 | Active, not recruiting | N/A | A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes | June 2014 | December 2027 |
| NCT05010629 | Active, not recruiting | Phase 2 | 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma | September 14, 2021 | August 30, 2025 |
| NCT05694819 | Active, not recruiting | Phase 2 | Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY) | April 17, 2020 | August 2024 |
| NCT03172624 | Active, not recruiting | Phase 2 | Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer | May 26, 2017 | May 2025 |
| NCT01969578 | Active, not recruiting | Phase 2 | Androgen Deprivation Therapy in Advanced Salivary Gland Cancer | September 24, 2015 | July 31, 2024 |
| NCT04249947 | Active, not recruiting | Phase 1 | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) | February 28, 2020 | September 2036 |
| NCT03781986 | Active, not recruiting | Phase 1/Phase 2 | APG-115 in Salivary Gland Cancer Trial | October 28, 2019 | January 2025 |
| NCT03319641 | Completed | N/A | PSMA-PET Imaging for Advanced ACC/SDC | October 25, 2017 | May 14, 2018 |
| NCT03602079 | Completed | Phase 1/Phase 2 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | July 16, 2018 | January 12, 2022 |
| NCT00886132 | Completed | Phase 2 | A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands | January 2007 | December 2012 |
| NCT01344356 | Completed | Phase 4 | Stereotactic Body Radiotherapy for Head and Neck Tumors | July 2008 | May 2018 |
| NCT01703455 | Completed | Phase 2 | Activity of Sorafenib in Salivary Gland Cancer | September 2010 | January 2013 |
| NCT00509002 | Completed | Phase 2 | Iressa Study in Patients With Salivary Gland Cancer | May 2004 | September 2016 |
| NCT05390294 | Completed | Survival With Patients Treated With Salivary Gland Cancer | January 1, 2022 | April 30, 2022 | |
| NCT04291300 | Completed | Phase 2 | Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients | May 26, 2020 | February 13, 2023 |
| NCT06091878 | Not yet recruiting | Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers | July 1, 2024 | January 31, 2026 | |
| NCT05898373 | Not yet recruiting | Phase 1/Phase 2 | Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC | June 7, 2023 | June 6, 2026 |
| NCT05074940 | Recruiting | Phase 2 | Amivantamab in Adenoid Cystic Carcinoma | August 5, 2022 | August 5, 2028 |
| NCT03942380 | Recruiting | N/A | Cell-free Tumor DNA in Head and Neck Cancer Patients | February 1, 2017 | February 1, 2025 |
| NCT04028479 | Recruiting | The Registry of Oncology Outcomes Associated With Testing and Treatment | May 5, 2021 | October 1, 2031 | |
| NCT04140526 | Recruiting | Phase 1/Phase 2 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | September 16, 2020 | December 31, 2027 |
| NCT04209660 | Recruiting | Phase 2 | Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers | June 2, 2020 | December 2024 |
| NCT04214353 | Recruiting | N/A | PSMA-PET Imaging Before and After ADT in Advanced SDC Patients | January 14, 2020 | September 2023 |
| NCT03360890 | Recruiting | Phase 2 | Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors | March 26, 2018 | September 2032 |
| NCT02628067 | Recruiting | Phase 2 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | December 18, 2015 | May 4, 2027 |
| NCT04620187 | Recruiting | Phase 2 | Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas | December 24, 2020 | February 1, 2026 |
| NCT03924466 | Recruiting | Phase 2 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients | April 1, 2019 | December 2024 |
| NCT02012699 | Recruiting | Integrated Cancer Repository for Cancer Research | November 1, 2013 | December 2099 | |
| NCT05483374 | Recruiting | The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers | May 31, 2022 | December 31, 2030 | |
| NCT03729297 | Terminated | Phase 2 | Cabozantinib in Advanced Salivary Gland Cancer Patients | September 5, 2018 | November 6, 2019 |
| NCT02042885 | Terminated | Phase 1/Phase 2 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer | January 2014 | February 2015 |
| NCT02401763 | Unknown status | Investigating the Role of Mucin and Mucin Glycosylating Enzymes in Nasopharyngeal Carcinoma and Salivary Gland Cancer and Their Correlation With Clinical Prognosis | April 2015 | ||
| NCT05008237 | Unknown status | Phase 2 | Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study | May 2, 2014 | May 2023 |
| NCT02048254 | Unknown status | Phase 3 | Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer | February 2014 | June 2018 |
| NCT04832438 | Withdrawn | Phase 2 | 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma | December 18, 2030 | June 18, 2034 |
- Disase is a (Disease Ontology)
- DOID:8618
- Cross Reference ID (Disease Ontology)
- ICD10CM:C08
- Cross Reference ID (Disease Ontology)
- ICD9CM:142.8
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:187648003
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0153362
- Exact Synonym (Disease Ontology)
- malignant neoplasm of salivary gland